68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Learn more about:
Related Clinical Trial
Drug Screening Using Novel IMD in ACC and Salivary Cancers 68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC) AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Understanding the Burden of ACC Through the Eyes of Patients A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Study of Everolimus (RAD001) in Combination With Lenalidomide MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Dovitinib in Adenoid Cystic Carcinoma Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Study of RAD001 in Adenoid Cystic Carcinoma

Brief Title

68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Official Title

Peking Union Medical College Hospital

Brief Summary

      This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating
      inhibitor, in metastatic adenoid cystic carcinoma(ACC)
    

Detailed Description

      68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been
      widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a
      rare epithelial malignant tumor, which usually originates from salivary glands. Its typical
      characteristics are long clinical course and high rate of distant metastasis. The purpose of
      this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid
      cystic carcinoma.
    


Study Type

Interventional


Primary Outcome

Standardized uptake value of 68Ga-FAPI in ACC

Secondary Outcome

 lesions detected by 68Ga-FAPI PET/CT

Condition

68Ga-FAPI PET/CT

Intervention

68Ga-FAPI

Study Arms / Comparison Groups

 68Ga-FAPI PET/CT
Description:  Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

October 1, 2021

Completion Date

December 31, 2022

Primary Completion Date

October 1, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  patients with ACC suspected metastatic tumor,and being able to provide basic
             information and sign the written informed consent form

        Exclusion Criteria:

          -  claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to
             fulfill the study
      

Gender

All

Ages

18 Years - 80 Years

Accepts Healthy Volunteers

No

Contacts

Zhaohui Zhu, +8619800370331, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT05499936

Organization ID

PUMCHFAPI-ACC


Responsible Party

Sponsor

Study Sponsor

Peking Union Medical College Hospital


Study Sponsor

Zhaohui Zhu, Study Chair, Peking Union Medical College Hospital


Verification Date

October 2021